MétaCan
Menu
Back to cohort
Record W2095477466 · doi:10.1097/qai.0b013e318230372e

Comparative Effectiveness of Initial Antiretroviral Therapy Regimens

2011· article· en· W2095477466 on OpenAlexafffund
Michael J. Mugavero, Margaret May, Heather J. Ribaudo, Roy M. Gulick, Sharon A. Riddler, Richard Haubrich, Sonia Napravnik, Sophie Abgrall, Andrew Phillips, Ross Harris, M. John Gill, Frank de Wolf, Robert S. Hogg, Huldrych F. Günthard, Geneviève Chêne, Antonella d’Arminio Monforte, Jodie L. Guest, Colette Smith, Javier Murillas, Juan Berenguer, Christoph Wyen, Peré Domingo, Mari M. Kitahata, Jonathan A C Sterne, Michael S Saag

Bibliographic record

VenueJAIDS Journal of Acquired Immune Deficiency Syndromes · 2011
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsUniversity of British ColumbiaUniversity of Calgary
FundersH2020 European Research CouncilNational Institute of Allergy and Infectious DiseasesCanadian Institutes of Health ResearchNational Institutes of HealthBristol-Myers SquibbUniversity of WashingtonGlaxoSmithKlineNational Institute of Mental HealthMedical Research CouncilACT Government
KeywordsAbacavirInternal medicineEfavirenzLopinavirConfidence intervalOdds ratioMedicineHazard ratioCohortViral loadAntiretroviral therapyHuman immunodeficiency virus (HIV)Immunology

Abstract

fetched live from OpenAlex

BACKGROUND: The generalizability of antiretroviral therapy (ART) clinical trial efficacy findings to routine care settings is not well studied. We compared the relative effectiveness of initial ART regimens estimated in AIDS Clinical Trial Group (ACTG) randomized controlled trials with that among patients receiving ART at Antiretroviral Therapy Cohort Collaboration (ART-CC) study sites. METHODS: Treatment-naive HIV-infected patients initiating identical ART regimens in ACTG trials (A5095 and A5142) and at 15 ART-CC cohort study sites were included. Virological failure (HIV-1 RNA >200 copies/mL) at 24 and 48 weeks, incident AIDS-defining events and mortality were measured according to study design (ART-CC cohort vs. ACTG trial) and stratified by third drug [abacavir (ABC), efavirenz (EFV), and lopinavir/r (LPV/r)]. We used logistic regression to estimate and compare odds ratios (OR) for virological failure between different regimens and study designs, and used Cox models to estimate and compare hazard ratios for AIDS and death. RESULTS: Compared with patients receiving ABC, those receiving EFV had roughly half the odds of 24-week virologic failure (>200 copies/mL) in both ACTG 5095 (OR = 0.53, 95% confidence interval: 0.36 to 0.79) and ART-CC (0.46, 0.37 to 0.57). Virologic superiority of EFV (vs. ABC) seemed comparable in ART-CC and ACTG 5095 (ratio of ORs 0.86, 95% confidence interval: 0.54 to 1.35). Odds ratios for 48-week virologic failure, comparing EFV with LPV/r, were also comparable in ACTG 5142 and ART-CC (ratio of ORs: 0.87, 0.45 to 1.69). CONCLUSIONS: Between ART regimen virologic efficacy of third drugs ABC, EFV, and LPV/r observed in the ACTG 5095 and 5142 trials seem generalizable to the routine care setting of ART-CC clinical cohorts.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.047
metaresearch head score (Gemma)0.105
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.047
Threshold uncertainty score0.246

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0470.105
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.004
Bibliometrics0.0030.002
Science and technology studies0.0000.001
Scholarly communication0.0030.002
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.326
Teacher spread0.271 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations23
Published2011
Admission routes2
Has abstractyes

Explore more

Same venueJAIDS Journal of Acquired Immune Deficiency SyndromesSame topicHIV/AIDS drug development and treatmentFrench-language works237,207